The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/ doi/10.1111/bph.12444/full.
Cytokine receptor family
Overview: Cytokines are not a clearly defined group of agents, other than having an impact on immune signalling pathways, although many cytokines have effects on other systems, such as in development. A feature of some cytokines, which allows them to be distinguished from hormones, is that they may be produced by "non-secretory" cells, for example, endothelial cells. Within the cytokine receptor family, some subfamilies may be identified, which are described elsewhere in the Guide to PHAR-MACOLOGY, receptors for the TNF family, the TGF-β family and the chemokines. Within this group of records are described Type I cytokine receptors, typified by interleukin receptors, and Type II cytokine receptors, exemplified by interferon receptors. These receptors possess a conserved extracellular region, known as the cytokine receptor homology domain (CHD), along with a range of other structural modules, including extracellular immunoglobulin (Ig)-like and fibronectin type III (FBNIII)-like domains, a transmembrane domain, and intracellular homology domains. An unusual feature of this group of agents is the existence of soluble and decoy receptors. These bind cytokines without allowing signalling to occur. A further attribute is the production of endogenous antagonist molecules, which bind to the receptors selectively and prevent signalling. A commonality of these families of receptors is the ligand-induced homo-or heterooligomerisation, which results in the recruitment of intracellular protein partners to evoke cellular responses, particularly in inflammatory or haematopoietic signalling. Although not an exclusive signalling pathway, a common feature of the majority of cytokine receptors is activation of the JAK/STAT pathway. This cascade is based around the protein tyrosine kinase activity of the Janus kinases (JAK), which phosphorylate the receptor and thereby facilitate the recruitment of signal transducers and activators of transcription (STATs). The activated homo-or heterodimeric STATs function principally as transcription factors in the nucleus.
Type I cytokine receptors are characterized by two pairs of conserved cysteines linked via disulfide bonds and a C-terminal WSXWS motif within their CHD. Type I receptors are commonly classified into five groups, based on sequence and structual homology of the receptor and its cytokine ligand, which is potentially more reflective of evolutionary relationships than an earlier scheme based on the use of common signal transducing chains within a receptor complex.
IL-2 receptor family
Overview: The IL-2 receptor family consists of one or more ligand-selective subunits, and a common γ chain (γc): IL2RG, P31785), though IL-4 and IL-7 receptors can form complexes with other receptor chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as a selective IL-2 receptor antagonist, which binds to IL-2 [3] . ---
IL-3 receptor family
Overview: The IL-3 receptor family signal through a receptor complex comprising of a ligand-specific α subunit and a common β chain (CSF2RB, P32927), which is associated with Jak2 and signals primarily through Stat5. 
IL-6 receptor family
Overview: The IL-6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL-6 signal transducer gp130 (IL6ST, P40189) or the oncostatin M-specific receptor, β subunit (OSMR, Q99650), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3-kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor is a glycerophosphatidylinositol-linked protein. Type II cytokine receptors also have two pairs of conserved cysteines but with a different arrangement to Type I and also lack the WSXWS motif.
Interferon receptor family
Overview: The interferon receptor family includes receptors for type I (α, β κ and ω) and type II (γ) interferons. There are at least 13 different genesencoding IFN-&ALPHA; subunits in a cluster on human chromosome 9p22: α1 (IFNA1, P01562), α2 (IFNA2, P01563), α4 (IFNA4, P05014), α5 (IFNA5, P01569), α6 (IFNA6, P05013), α7 (IFNA7, P01567), α8 (IFNA8, P32881), α10 (IFNA10, P01566), α13 (IFNA13, P01562), α14 (IFNA14, P01570), α16 (IFNA16, P05015), α17 (IFNA17, P01571) and α21 (IFNA21, P01568). Integrin ligands Collagen is the most abundant protein in metazoa, rich in glycine and proline residues, made up of crosslinked triple helical structures, generated primarily by fibroblasts. Extensive post-translational processing is conducted by prolyl and lysyl hydroxylases, as well as transglutaminases. Over 40 genes for collagen-α subunits have been identified in the human genome. The collagen-binding integrins α1β1, α2β1, α10β1 and α11β1 recognise a range of triple-helical peptide motifs including GFOGER (O = hydroxyproline), a synthetic peptide.
Laminin is an extracellular glycoprotein composed of α, β and γ chains, for which five, four and three genes, respectively, are identified in the human genome. It binds to α1β1, α2β1, α3,β1, α7β1 and α6β4 integrins10.
Fibrinogen is a glycosylated hexamer composed of two α (FGA, P02671), two β (FGB, P02675) and two γ (FGG, P02679,) subunits, linked by disulphide bridges. It is found in plasma and alpha granules of platelets. It forms cross-links between activated platelets mediating aggregation by binding αIIbβ3; proteolysis by thrombin cleaves short peptides termed fibrinopeptides to generate fibrin, which polymerises as part of the blood coagulation cascade.
Fibronectin is a disulphide-linked homodimer found as two major forms; a soluble dimeric form found in the plasma and a tissue version that is polymeric, which is secreted into the extracellular matrix by fibroblasts. Splice variation of the gene product (FN1, P02751) generates multiple isoforms.
Vitronectin is a serum glycoprotein and extracellular matrix protein (VTN, P04004) which is found either as a monomer or, following proteolysis, a disulphide -linked dimer.
Osteopontin forms an integral part of the mineralized matrix in bone (SPP1, P10451), where it undergoes extensive post-translation processing, including proteolysis and phosphorylation.
Von Willebrand factor (VWF, P04275) is a glycoprotein synthesised in vascular endothelial cells as a disulphide-linked homodimer, but multimerises further in plasma and is deposited on vessel wall collagen as a high molecular weight multimer. It is responsible for capturing platelets under arterial shear flow (via GPIb) and in thrombus propagation (via integrin αIIbβ3). Another family member is GC-C, the receptor for guanylin (GUCA2A, Q02747) and uroguanylin (GUCA2B, Q16661). Family members have conserved ligand-binding, catalytic (guanylyl cyclase) and regulatory domains with the exception of NPR-C which has an extracellular binding domain homologous to that of other NPRs, but with a truncated intracellular domain which appears to couple, via the Gi/o family of G-proteins, to activation of phospholipase C, inwardly-rectifying potassium channels and inhibition of adenylyl cyclase activity [25] .
Potency order ANP (NPPA, P01160) ≥ BNP (NPPB, P16860) >> CNP (NPPC, P23582) [27] CNP (NPPC, P23582) >> ANP (NPPA, P01160) >> BNP (NPPB, P16860) [27] ANP (NPPA, P01160) > CNP (NPPC, P23582) ≥ BNP (NPPB, P16860) [27] uroguanylin (GUCA2B, Q16661) > guanylin (GUCA2A, Q02747)
Endogenous agonists ANP (NPPA, P01160) (Selective) [26] , BNP (NPPB, P16860) (Selective) [26] CNP (NPPC, P23582) (Selective) [27] 
Pattern Recognition receptors
Overview: Pattern recognition receptors (PRR, [42] ) participate in the innate immune response to microbial agents, the stimulation of which leads to activation of intracellular enzymes and regulation of gene transcription. PRR include both cell-surface and intracellular proteins, including toll-like receptors (TLR), nucleotide-binding oligomerization domain-like receptors (NLR, also known as NOD-like receptors) and the mannose receptor family (ENSFM00250000004089). PRR may be divided into signalling-associated members, identified here, and endocytic members (such as the mannose receptor family), the function of which appears to be to recognise particular microbial motifs for subsequent cell attachment, internalisation and destruction.
PRRs express multiple leucine-rich regions to bind a range of microbially-derived ligands, termed PAMPs or pathogenassociated molecular patterns, which includes peptides, carbohydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and nucleic acids.
Toll-like receptor family
Overview: Members of this family share significant homology with the interleukin-1 receptor family and appear to require dimerization either as homo-or heterodimers for functional activity. Heterodimerization appears to influence the potency of ligand binding substantially (e.g. TLR1/2 and TLR2/6, [43] [44] ). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are cell-surface proteins, while other members are associated with intracellular organelles, signalling through the MyD88-dependent pathways (with the exception of TLR3). As well as responding to exogenous infectious agents, it has been suggested that selected members of the family may be activated by endogenous ligands, such as hsp60 (HSPD1, P10809) [38] . 
NOD-like receptor family
Overview: Structural analysis has identified a common motif of a mid-peptide located nucleotide-binding and oligomerization (NACHT) domain, which allows division of NOD-like receptors into three subfamilies, NLRC (or NODs), NLRP (or NALP) and IPAF [40] . NLRC members are named on the basis of a sequence motif expressed at their N-termini, the caspase recruitment domain (CARD), while NLRP members have a pyrin domain. NLRs express C-terminal leucine-rich regions which have regulatory function and appear to recognize the microbial products to which the NLRs respond. NLRC family members recruit a serine/threonine kinase RIPK2 (receptor-interacting serine/ threonine kinase 2, O43353, also known as CARD3, CARDIAK, RICK, RIP2) leading to signalling through NFκB and MAP kinase. NLRP family members, upon activation, recruit adaptor proteins (e.g. ASC, also known as PYCARD, CARD5, TMS-1, Q9ULZ3). Activated NLRs associate in multiprotein complexes, known as inflammasomes [40] , allowing the recruitment of caspases. 
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NLRP3, Q96P20 -Multiple virus particles have been shown to act as agonists, including Sendai and influenza
Receptor serine/threonine kinase (RSTK) family
Overview: Receptor serine/threonine kinases (RTSK), EC 2.7.11.30, respond to particular cytokines, the transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) families, and may be divided into two subfamilies on the basis of structural similarities. Agonist binding initiates formation of a cell-surface complex of type I and type II RSTK, possibly heterotetrameric, where where both subunits express serine/threonine kinase activity. The type I receptor serine/threonine kinases (ENSFM00250000000213) are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7 Endogenous agonists, approximately 30 in man, are often described as paracrine messengers acting close to the source of production. They are characterized by six conserved cysteine residues and are divided into two subfamilies on the basis of sequence comparison and signalling pathways activated, the TGFβ/activin/nodal subfamily and the BMP/GDF (growth/ differentiation factor)/MIS (Müllerian inhibiting substance) subfamily. Ligands active at RSTKs appear to be generated as large precursors which undergo complex maturation processes [47] . Some are known to form disulphide-linked homo-and/or heterodimeric complexes. Thus, inhibins are α subunits linked to a variety of β chains, while activins are combinations of β subunits.
Type I receptor serine/threonine kinases

Overview:
The type I receptor serine/threonine kinases (ENSFM00250000000213) are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7). 
Müllerian inhibiting substance (AMH, P03971)
Comments: A number of endogenous inhibitory ligands have been identified for RSTKs, including BMP3, inhibinα, inhibinβC and inhibinβE.
An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors [50] . The authors confirmed the selectivity of SB505124 to inhibit TGFβ signalling through ALK4, ALK5, ALK7 [46] . dorsomorphin inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase [51] .
Smads were identified as mammalian orthologues of Drosophila genes termed "mothers against decapentaplegic" and may be divided into Receptor-regulated Smads (R-Smads, including Smad1, Smad2, Smad3, Smad5 and Smad8), Co-mediated Smad (Co-Smad, Smad4) and Inhibitory Smads (I-Smad, Smad6 and Smad7). R-Smads form heteromeric complexes with Co-Smad. I-Smads compete for binding of R-Smad with both receptors and Co-Smad. RTKs are of widespread interest not only through physiological functions, but also as drug targets in many types of cancer and other disease states. Many diseases result from genetic changes or abnormalities that either alter the activity, abundance, cellular distribution and/or regulation of RTKs. Therefore, drugs that modify the dysregulated functions of these RTKs have been developed which fall into two categories. One group is often described as 'biologicals', which block the activation of RTKs directly or by chelating the cognate ligands, while the second are small molecules designed to inhibit the tyrosine kinase activity directly.
Type I RTKs: ErbB (epidermal growth factor) receptor family
Overview: ErbB family receptors are Class I receptor tyrosine kinases [65] . ERBB2 (also known as HER-2 or NEU; ERBB2, P04626) appears to act as an essential partner for the other members of the family without itself being activated by a cognate ligand [66] . Ligands of the ErbB family of receptors are peptides, many of which are generated by proteolytic cleavage of cellsurface proteins. HER/ErbB is the viral counterpart to the receptor tyrosine kinase EGFR. All family members heterodimerize with each other to activate downstream signalling pathways and are aberrantly expressed in many cancers, particularly forms of breast cancer. 
Type II RTKs: Insulin receptor family
Overview: The circulating peptide hormones insulin (INS, P01308) and the related insulin-like growth factors (IGF) activate Class II receptor tyrosine kinases [65] , to evoke cellular responses, mediated through multiple intracellular adaptor proteins. Exceptionally amongst the catalytic receptors, the functional receptor in the insulin receptor family is derived from a single gene product, cleaved post-translationally into two peptides, which then cross-link via disulphide bridges to form a heterotetramer. Intriguingly, the endogenous peptide ligands are formed in a parallel fashion with post-translational processing producing a heterodimer linked by disulphide bridges. Signalling through the receptors is mediated through a rapid autophosphorylation event at intracellular tyrosine residues, followed by recruitment of multiple adaptor proteins, notably IRS1 (P35568), IRS2 (Q9Y4H2), SHC1 (P29353), GRB2 (P62993) and SOS1 (Q07889).
Serum levels of free IGFs are kept low by the action of IGF binding proteins (IGFBP1-5, P08833, P18065, P17936, P22692, P24593), which sequester the IGFs; overexpression of IGFBPs may induce apoptosis, while IGFBP levels are also altered in some cancers.
Nomenclature
Insulin receptor Insulin-like growth factor I Insulin receptor-related receptor
Endogenous ligands insulin (INS, P01308) IGF1 (IGF1, P05019), IGF2 (IGF2, P01344) -
Comments:
There is evidence for low potency binding and activation of insulin receptors by IGF1. IGF2 also binds and activates the cation-independent mannose 6-phosphate receptor (also known as the insulin-like growth factor II receptor), which lacks classical signalling capacity and appears to subserve a trafficking role [72] . INSRR, which has a much more discrete localization, being predominant in the kidney [69] , currently lacks a cognate ligand or evidence for functional impact.
Antibodies targetting IGF1, IGF2 and the extracellular portion of the IGF1 receptor are in clinical trials.
PQ401 inhibits the insulin-like growth factor receptor [56] , while BMS-536924 inhibits both the insulin receptor and the insulinlike growth factor receptor [85] .
Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Overview: Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo-or heterodimers. Endogenous ligands of PDGF receptors are homo-or heterodimeric: PDGFA, PDGFB, VEGFE and PDGFD combine as homo-or heterodimers to activate homo-or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer. 
'-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [57] Comments: Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3), as well as pan-type III RTK inhibitors such as sunitinib and sorafenib [78] ; 5'-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [53] .
Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Overview: VEGF receptors are homo-and heterodimeric proteins, which are characterized by seven Ig-like loops in their extracellular domains and a split kinase domain in the cytoplasmic region. They are key regulators of angiogenesis and lymphangiogenesis; as such, they have been the focus of drug discovery for conditions such as metastatic cancer. Splice variants of VEGFR1 and VEGFR2 generate truncated proteins limited to the extracellular domains, capable of homodimerisation and binding VEGF ligands as a soluble, non-signalling entity. Ligands at VEGF receptors are typically homodimeric. VEGFA (VEGFA, P15692) is able to activate VEGFR1 homodimers, VEGFR1/2 heterodimers and VEGFR2/3 heterodimers. VEGFB (VEGFB, P49765) and placental growth factor activate VEGFR1 homodimers, while VEGFC (VEGFC, P49767) and VEGFD (FIGF, O43915) activate VEGFR2/3 heterodimers and VEGFR3 homodimers, and, following proteolysis, VEGFR2 homodimers.
Nomenclature fms-related tyrosine kinase 1 kinase insert domain receptor (a type III receptor tyrosine kinase) fms-related tyrosine kinase 4
Common abbreviation VEGFR-1 VEGFR-2 VEGFR-3
Endogenous ligands VEGFA (VEGFA, P15692), VEGFB (VEGFB, P49765) VEGFA (VEGFA, P15692), VEGFC (VEGFC, P49767), VEGFE (PDGFC, Q9NRA1)
VEGFC (VEGFC, P49767), VEGFD (FIGF, O43915), VEGFE (PDGFC, Q9NRA1)
Comments: The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 [62] , Ki8751 [68] and ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity [84] are described as VEGFR2-selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF-A, used clinically for the treatment of certain metastatic cancers; an antibody fragment has been used for wet age-related macular degeneration. Comments: Splice variation of the receptors can influence agonist responses. FGFRL1 (Q8N441) is a truncated kinase-null analogue.
Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors [71, 87] . PD161570 is an FGFR tyrosine kinase inhibitor [54] , while PD173074 has been described to inhibit FGFR1 and FGFR3 [80] .
Type VII RTKs: Neurotrophin receptor/Trk family
Overview:
The neurotrophin receptor family of RTKs include trkA, trkB and trkC (tropomyosin-related kinase) receptors, which respond to NGF, BDNF and neurotrophin-3, respectively. They are associated primarily with proliferative and migration effects in neural systems. Various isoforms of neurotrophin receptors exist, including truncated forms of trkB and trkC, which lack catalytic domains. p75(TNFRSF16, also known as nerve growth factor receptor), which has homologies with tumour necrosis factor receptors, lacks a tyrosine kinase domain, but can signal via ceramide release and nuclear factor κB (NF-κB) activation. Both trkA and trkB contain two leucine-rich regions and can exist in monomeric or dimeric forms. ]BDNF have been used to label the trkA and trkB receptor, respectively. p75 influences the binding of NGF (NGF, P01138) and NT-3 (NTF3, P20783) to trkA. The ligand selectivity of p75 appears to be dependent on the cell type; for example, in sympathetic neurones, it binds NT-3 (NTF3, P20783) with comparable affinity to trkC [60] .
Small molecule agonists of trkB have been described, including LM22A4 [73] , while ANA12 has been described as a noncompetitive antagonist of BDNF binding to trkB [56] . GNF5837 is a family-selective tyrosine kinase inhibitor [52] , while the tyrosine kinase activity of the trkA receptor can be inhibited by GW441756 (pIC50= 8.7, [86] ) and tyrphostin AG879 [76] .
Type VIII RTKs: ROR family
Overview: Members of the ROR family (ENSFM00510000502747) appear to be activated by ligands complexing with other cell-surface proteins. Thus, ROR1 and ROR2 appear to be activated by Wnt-5a (WNT5A, P41221) binding to a Frizzled receptor thereby forming a cell-surface multiprotein complex [67] . Comments: PF04217903 is a selective Met tyrosine kinase inhibitor [58] . SU11274 is an inhibitor of the HGF receptor [79] , with the possibility of further targets [53] .
Type XI RTKs: TAM (TYRO3-, AXL-and MER-TK) receptor family
Overview: Members of this RTK family (ENSFM00500000269872) represented a novel structural motif, when sequenced. The ligands for this family, Gas6 (GAS6, Q14393) and protein S (PROS1, P07225), are secreted plasma proteins which undergo vitamin K-dependent post-translational modifications generating carboxyglutamate-rich domains which are able to bind to negatively-charged surfaces of apoptotic cells. Comments: AXL tyrosine kinase inhibitors have been described [74] .
Type XII RTKs: TIE family of angiopoietin receptors
Overview: The TIE family were initially associated with formation of blood vessels. Endogenous ligands are angiopoietin-1 (ANGPT1, Q15389), angiopoietin-2 (ANGPT2, O15123), and angiopoietin-4 (ANGPT4, Q9Y264). angiopoietin-2 (ANGPT2, O15123) appears to act as an endogenous antagonist of angiopoietin-1 function. 
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Type XVI RTKs: DDR (collagen receptor) family
Overview: Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in man, with at least 29 families of genes encoding proteins, which undergo splice variation and posttranslational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded, twine-like structure. In man, principal family members include COL1A1 (COL1A1, P02452), COL2A1 (COL2A1, P02458), COL3A1 (COL3A1, P02461) and COL4A1 (COL4A1, P02462).
Nomenclature discoidin domain receptor tyrosine kinase 1 discoidin domain receptor tyrosine kinase 2
Common abbreviation DDR1 DDR2
HGNC, UniProt DDR1, Q08345 DDR2, Q16832
Comments:
The tyrosine kinase inhibitors of DDR, imatinib and nilotinib, were identified from proteomic analysis [59] .
Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Overview: The LTK family (ENSFM00500000270379) appear to lack endogenous ligands. LTK is subject to tissue-specific splice variation, which appears to generate products in distinct subcellular locations. Alk fusions derived from gene translocations are associated with large cell lymphomas and inflammatory myofibrilastic tumours. Comment -crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase activity [64] Tumour necrosis factor (TNF) receptor family Comments: TNFRSF1A is preferentially activated by the shed form of TNF ligand, whereas the membrane-bound form of TNF serves to activate TNFRSF1A and TNFRSF1B equally. The neurotrophins nerve growth factor (NGF (NGF, P01138), P01138), brain-derived neurotrophic factor (BDNF (BDNF, P23560), P23560), NT-3 (NTF3, P20783) (NTF3, P20783) and NT-4 (NTF4, P34130) (NTF4, P34130) are structurally unrelated to the TNF ligand superfamily but exert some of their actions through the "low affinity nerve growth factor receptor" (NGFR (TNFRSF16)) as well as through the TRK family of receptor tyrosine kinases.
